Roche reports narrow failure of breast cancer pill in Phase 3 trial at ASCO

Roche updated investors and the oncology community that its experimental breast cancer oral therapy did not meet its primary endpoint in a pivotal Phase 3 study.

The data, presented at the American Society of Clinical Oncology meeting, showed a narrow miss in the predefined efficacy criteria, confirming the earlier March announcement of the setback.

The failure undermines the company's earlier expectation that the drug could generate billions in sales, and analysts will reassess its impact on Roche's oncology pipeline.

Roche said it will review the results in detail and consider next steps, which may include additional analyses or alternative development strategies.